Table 4 Univariate Cox regression of disease free and overall survival in the 122 patients adjuvantly treated with 5FU chemotherapy for at least three cycles
DFS | OS | ||||||||
|---|---|---|---|---|---|---|---|---|---|
n | Events | P | HR | 95% CI | Events | P | HR | 95% CI | |
Sex | |||||||||
Female | 41 | 13 | 0.86 | 1 | — | 7 | 0.60 | 1 | — |
Male | 81 | 27 | 1.06 | 0.55–2.06 | 17 | 1.26 | 0.52–3.05 | ||
Age (years) | |||||||||
<65 | 60 | 13 | 0.003 | 1 | — | 9 | 0.08 | 1 | — |
⩾65 | 62 | 27 | 2.90 | 1.46–5.79 | 15 | 2.12 | 0.91–4.91 | ||
Dukes’ stage | |||||||||
B2 | 46 | 10 | 0.04 | 1 | — | 6 | 0.16 | 1 | — |
C | 76 | 30 | 2.10 | 1.02–4.30 | 18 | 1.94 | 0.77–4.89 | ||
Toxicity grade | |||||||||
0–2 | 81 | 25 | 0.43 | 1 | — | 17 | 0.68 | 1 | — |
3–4 | 41 | 15 | 1.30 | 0.68–2.47 | 7 | 0.83 | 0.34–2.01 | ||
TYMS VNTR | |||||||||
2R2R | 23 | 11 | 0.24 | 1 | — | 7 | 0.34 | 1 | — |
2R3R | 57 | 18 | 0.63 | 0.30–1.35 | 12 | 0.72 | 0.28–1.83 | ||
3R3R | 42 | 11 | 0.49 | 0.21–1.14 | 5 | 0.42 | 0.13–1.34 | ||
TYMS G>C | |||||||||
Low activity | 68 | 23 | 0.79 | 1 | — | 15 | 0.58 | 1 | — |
High activity | 54 | 17 | 0.92 | 0.49–1.72 | 9 | 0.79 | 0.35–1.81 | ||
TYMS 3′UTR | |||||||||
ins/ins | 44 | 13 | 0.65 | 1 | — | 8 | 0.67 | 1 | — |
ins/del | 63 | 24 | 1.29 | 0.66–2.53 | 15 | 1.30 | 0.55–3.06 | ||
del/del | 15 | 3 | 0.84 | 0.24–2.98 | 1 | 0.59 | 0.07–4.80 | ||
TYMS comb. A | |||||||||
Low | 64 | 25 | 0.15 | 1 | — | 16 | 0.22 | 1 | — |
High | 58 | 15 | 0.62 | 0.33–1.18 | 8 | 0.58 | 0.24–1.38 | ||
TYMS comb. B | |||||||||
Low activity | 32 | 12 | 0.69 | 1 | — | 8 | 0.58 | 1 | — |
Intermediate | 82 | 26 | 0.74 | 0.37–1.48 | 15 | 0.64 | 0.27–1.50 | ||
High activity | 8 | 2 | 0.71 | 0.16–3.17 | 1 | 0.64 | 0.08–4.95 | ||
MTHFR C677T | |||||||||
C/C | 41 | 13 | 0.54 | 1 | — | 8 | 0.86 | 1 | — |
C/T | 59 | 18 | 0.85 | 0.42–1.74 | 11 | 0.83 | 0.33–2.06 | ||
T/T | 22 | 9 | 1.34 | 0.57–3.14 | 5 | 1.07 | 0.35–3.27 | ||
MTHFR A1298C | |||||||||
A/A | 49 | 17 | 0.73 | 1 | — | 9 | 0.86 | 1 | — |
A/C | 57 | 19 | 0.82 | 0.42–1.60 | 13 | 1.01 | 0.43–2.38 | ||
C/C | 16 | 4 | 0.68 | 0.23–2.02 | 2 | 0.67 | 0.14–3.10 | ||
MTHFR comb. | |||||||||
Low | 41 | 12 | 0.30 | 1 | — | 9 | 0.95 | 1 | — |
Intermediate | 72 | 26 | 1.62 | 0.81–3.24 | 13 | 1.10 | 0.46–2.59 | ||
High | 9 | 2 | 0.83 | 0.18–3.72 | 2 | 1.28 | 0.27–5.98 | ||
CL (l min–1 Kg–1) | |||||||||
<0.017 | 61 | 16 | 0.17 | 1 | — | 6 | 0.032 | 1 | — |
⩾0.017 | 61 | 24 | 1.56 | 0.83–2.95 | 18 | 2.76 | 1.09–6.99 | ||
% Dose reduction | Continuous | 0.16 | 1.02 | 0.99–1.04 | 0.27 | 1.02 | 0.99–1.04 | ||
